/// NEWS
2021 May 31
Approval at the Sugarloaf Mountain
Bioabsorbable MAGNEZIX® CBS approved for medical use in Brazil. >>
We help to sustainably lower costs.
Innovations in the health sector usually tend to first push costs higher. Some optimisation approaches of this kind only bring benefits after many years or even many decades of use. Not so with MAGNEZIX®: this innovation pays for itself very quickly.
Everyone can profit from the benefits of MAGNEZIX®
The question all health insurance companies ask themselves: Is innovation affordable? The answer is clear: yes, THIS one is - and has even more benefits:
- Avoids the costs of a second operation: The use of MAGNEZIX® implants eliminates material removal - the material itself becomes bone. No second surgery, no further surgery and infection risks.
- Avoiding complications: Infections around the implant site or wound healing disorders are rarely observed in the first procedure, which usually leads to a timely release or a complication-free treatment of patients. The anti-infectious effects of magnesium are another positive factor.
- Shorten the downtime and sickness: Thanks to the osteoconductive properties of MAGNEZIX® the healing process is positively influenced. Employers and workers benefit from the elimination of the second surgery, because no second sick leave is necessary.
Estimates reveal that the savings alone from avoiding operations to remove material are worth up to several hundred million Euros in Germany alone. The macro-economic benefits of this new technology are therefore good news for everyone - patients, clinics, doctors and health insurance companies.
And that is just the beginning
Leading health insurance companies in Germany recognized the advantages of the world's first approved metal implants, and are currently setting up pilot projects to determine the satisfaction of patients, doctors and insurance companies.
And in the international arena as well, politicians are endeavouring to use innovations to make their health services more efficient in the long term (for instance, Precision Medicine Initiative in the USA, Continuing Clinical Innovation Scheme in the United Kingdom).
Syntellix's current product portfolio is being continually expanded. The launching of new product lines will give rise to further palpable reductions in costs in future associated with orthopaedic surgery.
Conclusions: from the health insurance companies, employers' liability insurance schemes, army, or other funding agencies - we are here to help you reduce your costs!
We will be happy to put together a comprehensive package of information material for you, as well as present MAGNEZIX® to you personally.
Simply use the contact form or send us an email: info@syntellix.com
The figures tell a clear story
The following facts and figures clearly highlight the savings potential available by using MAGNEZIX®.
The background:
- 4,500,000 musculo-skeletal operations are carried out in Germany every year [OPS-Codes 5-78 to 5-86]
- The infection rate is up to 4.5 %, the average costs are approx. € 10,000.00 per treatment
- Loss of gross productivity per day off sick per employee: € 165.00/day
- 3.9 % of the implants must be removed again during a second operation, including hospitalization
- 7.8 % of the implants have to be removed again in a second out-patient operation
Robert Koch-Institute (rki.de), Federal Health Report (gbe-bund.de), Federal Occupational Health and Safety Agency (baua.de), National Association of Statutory Health Insurance Funds (gkv-spitzenverband.de), InEK – Institute for Hospital Remuneration Systems (g-drg.de), Uniform Evaluation Scales (EBM) of the Association of Statutory Health Insurance Physicians, Osteosynthesis Working Group – Association for the Study of Internal Fixation (AO/AO-ASIF). As at 2014.
The costs:
Of these at least 4,500,000 implants, 11.7 % had to be removed again, and the associated financial costs totaled:
- € 515,000,000 inpatient operation and treatment costs
- € 145,000,000 outpatient operation and treatment costs
- € 240,000,000 treatment costs for infections
- € 190,000,000 loss of gross productivity
Implant removal costs in Germany sum up to 1.095.000.000 Euro per year!
Additional health risks
In addition, the removal of osteosynthesis implants are associated with considerable risks in part as revealed by various scientific investigations (in % of the investigated cases):
- General complications
- Refracture of the bone after removal
- Nerve damage
- Removal not possible
- Post-operative infections
- Pain after the surgery
12 % - 40 %
27 %
5 % - 40 %
up to 9 %
up to 20 %
7 % - 20 %
Bostman O, Pihajamaki H. Routine implant removal after fracture surgery: a potentially reducible consumer of hospital resources in trauma units. J Trauma.1996;41:846-9
Minkowitz RB, Bhadsavle S, Walsh M, Egol KA. Removal of Painful Orthopaedic Implants After Fracture Union. J Bone Joint Durg AM. 2007;89:1906-1912
Hanson B, van der Werken C, Stengel . Surgeon‘s beliefs and perceptions about removal of orthopaedic implants. BMC Musculoskeletal Disorders 2008, 9:73